Curanex Pharmaceuticals Meets Nasdaq Listing Requirement

Curanex Pharmaceuticals Inc. announced it has regained compliance with Nasdaq's minimum bid price rule. The company's common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days, from August 20 to September 2, 2026. This resolution formally closes the previous delisting matter, ensuring its continued listing on Nasdaq.